Please ensure Javascript is enabled for purposes of website accessibility

Why Emergent BioSolutions Shares Are Crashing Today

By Keith Speights – Jun 8, 2020 at 10:33AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An adverse court decision is weighing on the biotech stock.

What happened

Shares of Emergent BioSolutions (EBS 2.19%) were crashing 18.4% lower as of 11:13 a.m. EDT on Monday. The big drop came after the U.S. District Court for the District of New Jersey reached a decision after the market closed on Friday in a patent lawsuit regarding opioid overdose treatment NARCAN, a nasal spray. The court ruled in favor of Teva Pharmaceuticals (TEVA 0.65%) and against Emergent and its partner, Opiant Pharmaceuticals.

So what

The decision by the U.S. District Court is a huge blow to Emergent. NARCAN generated $72.2 million in sales for the company in the first quarter of 2020, nearly 38% of its total revenue.

Gavel on top of $100 bills

Image source: Getty Images.

Technically, the court decision applies only to the NARCAN 4 mg nasal spray. Emergent also markets a 2 mg version of the product. However, Emergent and Opiant are also in litigation with Teva over the lower-dose version of the product.

Should the court's ruling stand, Emergent will face generic competition from Teva for its top-selling product. It also is involved in similar patent litigation with Perrigo over NARCAN 4 mg nasal spray. 

Now what

Emergent BioSolutions stated that it intends to appeal the decision by the U.S. District Court. The company, though, plans to provide an update to its 2020 financial outlook as a result of the negative ruling when it announces its second-quarter results.

In the meantime, the main catalysts to look forward to with the biotech stock are related to its COVID-19 efforts. Emergent recently won a contract with the U.S. government worth around $628 million to manufacture novel coronavirus vaccines. It's also developing plasma-derived therapies targeting COVID-19.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Emergent BioSolutions. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Emergent BioSolutions Inc. Stock Quote
Emergent BioSolutions Inc.
EBS
$20.53 (2.19%) $0.44
Teva Pharmaceutical Industries Limited Stock Quote
Teva Pharmaceutical Industries Limited
TEVA
$7.74 (0.65%) $0.05
Perrigo Company plc Stock Quote
Perrigo Company plc
PRGO
$36.17 (-3.96%) $-1.49
Opiant Pharmaceuticals, Inc. Stock Quote
Opiant Pharmaceuticals, Inc.
OPNT
$10.16 (-3.24%) $0.34

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
327%
 
S&P 500 Returns
105%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.